

Speakers

Carlos L. Arteaga, MD

Director, Center for Cancer Targeted Therapies and Breast Cancer Program, Vanderbilt-Ingram Cancer Center

Trever Bivona, MD, PhD

Associate Professor, Division of Hematology/Oncology, UC San Francisco

Gideon E. Bollag, PhD

Chief Executive Officer, Plexxikon

Marie Classon, PhD

Scientist, Genentech, Inc.

Ryan B. Corcoran, MD, PhD

Translational Research Director, Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital Cancer Center

Jennifer Grandis, MD

Director, UCSF Clinical and Translational Science Institute
Professor, Department of Otolaryngology Head and Neck Surgery, UC San Francisco

Paul Mischel, MD

Professor, Department of Pathology, UC San Diego; Ludwig Institute for Cancer Research

James Rubenstein, MD, PhD

Professor in Residence, Division of Hematology/Oncology, UC San Francisco

Charles L. Sawyers, MD

Chair, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center

Kevin M. Shannon, MD

Professor, Department of Pediatrics, UC San Francisco

Padmanee Sharma, MD, PhD

Professor, Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center

Alice T. Shaw, MD, PhD

Associate Professor of Medicine, Harvard Medical School


Dennis Slamon, MD, PhD

Professor, Chief, and Executive Vice Chair for Research, Department of Medicine, Hematology/Oncology, UCLA Medical Center

Catherine C. Smith, MD

Assistant Professor, Division of Hematology/Oncology, UC San Francisco

UCSF Helen Diller Family
Comprehensive
Cancer Center



Cancer Center Symposium 2016

Unraveling and Overriding Mechanisms of Resistance to Cancer Therapeutics

Wednesday, November 16, 2016

9:00 am - 4:50 pm

Thursday, November 17, 2016

9:00 am - 12:40 pm

UCSF Mission Bay
Byers Auditorium, Genentech Hall

cancer.ucsf.edu/symposium

Event Sponsors

ARIAD

Avella Specialty Pharmacy

Bristol-Myers Squibb

Celgene Corporation

Exelixis

Genentech

Incyte

Jazz Pharmaceuticals

Pfizer Oncology

Revolution Medicines

TESARO

Third Rock Ventures

Wednesday, November 16, 2016

9:00 am Welcome

[Session 1 \(Chair: Neil Shah, MD, PhD\)](#)

9:10 am *Keynote presentation:*
New twists on cancer drug resistance
Charles Sawyers, MD

10:10 am Break

[Session 2 \(Chair: Luika Timmerman, PhD\)](#)

10:20 am **Epigenetic repression of retrotransposons in cancer cell drug tolerance**
Marie Classon, PhD

11:00 am **From the clinic to the lab: Investigating immune responses to immune checkpoint therapies**
Padmanee Sharma, MD, PhD

11:40 am **Overcoming tumor heterogeneity and resistance in gastrointestinal cancers**
Ryan B. Corcoran, MD, PhD

12:20 pm Lunch

[Session 3 \(Chair: Chloe Atreya, MD, PhD\)](#)

1:20 pm **Overcoming pharmacokinetic resistance by targeting a metabolic co-dependency in brain cancer**
Paul Mischel, MD

2:00 pm **Genomic mediators of treatment resistance in head and neck cancer**
Jennifer Grandis, MD

2:40 pm **New insights into the molecular basis of lung cancer progression**
Trever Bivona, MD, PhD

3:20 pm Break

[Session 4 \(Chair: Catherine Smith, MD\)](#)

3:30 pm **Strategies to overcome resistance to BRAF and KIT inhibitors**
Gideon E. Bollag, PhD

4:10 pm **In vivo forward screens to uncover mechanisms of resistance in leukemias driven by hyperactive Ras**
Kevin M. Shannon, MD

4:50 pm Adjourn

Thursday, November 17, 2016

9:00 am Welcome

[Session 5 \(Chair: Mark Moasser, MD\)](#)

9:10 am **Therapeutic resistance in oncogene-driven lung cancer**
Alice T. Shaw, MD, PhD

9:50 am **Resistance to lenalidomide in aggressive B-cell lymphoma**
James Rubenstein, MD, PhD

10:30 am **Resistance to HER2-targeted therapy**
Dennis Slamon, MD, PhD

11:10 am Break

[Session 6 \(Chair: Arun Wiita, MD, PhD\)](#)

11:20 am **Mechanisms of resistance to endocrine therapy: Insights from translational studies in breast cancer**
Carlos L. Arteaga, MD

12:00 pm **Polyclonal resistance to FLT3 inhibitors in AML**
Catherine C. Smith, MD

12:40 pm Adjourn

Session Chairs

Chloe Atreya, MD, PhD
Assistant Clinical Professor, Division of Hematology/Oncology, UCSF

Mark Moasser, MD
Professor, Division of Hematology/Oncology, UCSF

Neil Shah, MD, PhD
Associate Professor, Division of Hematology/Oncology, UCSF
Program Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center

Catherine C. Smith, MD
Assistant Professor, Division of Hematology/Oncology, UCSF

Luika Timmerman, PhD
Assistant Researcher, UCSF Helen Diller Family Comprehensive Cancer Center

Arun Wiita, MD, PhD
Assistant Professor, Department of Laboratory Medicine, UCSF